CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

ALL CONTRIBUTIONS

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.
Read
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength.
Read
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.
Read
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Small-cap speculative biotech stocks regain interest with volatility.
Read
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning.
Read
Uncertainty Grips Markets, On A Clear Day Maybe You Can See A Week Ahead
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Read

Comments

Latest Comments
Regulatory News For Rare Disease Products - Hot Stocks: BLUE, ICPT, SRPT
7 years ago

Getting trial information and following them is the hard part as it takes too much time. Just sett up the stocks in a Yahoo portfolio and track daily. The WEB site of the Company usually lets you know if trial results are coming in and when.

In this article: BLUE, ICPT, SRPT
Biotech Buzz Is Broken
7 years ago

Here is the YTD for KITE down 4.7%:

www.google.com/finance

In this article: JUNO, KITE, GILD, REGN
2015 Biotech Stock Preview: Rhythms Of The “PermaBull”
8 years ago

prefer a fund like FBIOX but XBI will work when the market heats up

In this article: XLV, FBT, FBIOX, GILD
1 to 3 of 3 comments

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts
Biotech Investing Strategy For 2020: Part I… Update-1 Jan 24
We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle.
Asco Rally Fizzles: The Nascent Rally In Biotech Stocks Fades
ASCO Rally Fizzles Two Weeks ahead of May 31-June 4 Meeting: XBI down 0.9% to $83.

Work Experience

CEO
Raygent Associates
January 1990 - Present (33 years 7 months)
Biotechnology Intelligence www.raygent.com

Education

Penn State University
BS
Biochemistry
Rutgers University
MBA
Business

Publications